AU2001223953A1 - Use of l-carnitine as stabilizing agent of proteins - Google Patents

Use of l-carnitine as stabilizing agent of proteins

Info

Publication number
AU2001223953A1
AU2001223953A1 AU2001223953A AU2395301A AU2001223953A1 AU 2001223953 A1 AU2001223953 A1 AU 2001223953A1 AU 2001223953 A AU2001223953 A AU 2001223953A AU 2395301 A AU2395301 A AU 2395301A AU 2001223953 A1 AU2001223953 A1 AU 2001223953A1
Authority
AU
Australia
Prior art keywords
proteins
carnitine
stabilizing agent
chaperone
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001223953A
Inventor
Menotti Calvani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of AU2001223953A1 publication Critical patent/AU2001223953A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to the technical field of stabilizing proteins, in particular to the therapeutic aspects of protein stabilization. L-carnitine is a useful agent for stabilizing proteins, and in a particularly favourable aspect in proteins used in the medical field. In a preferred aspect, L-carnitine is used for protecting chaperone activity, and in the medical field for preserving the activity of altered chaperone proteins. In connection with this invention L-carnitine is used for the preparation of a medicament for the treatment of diseases due to altered chaperone proteins, such as eye diseases, in particular cataract.
AU2001223953A 2000-12-15 2000-12-15 Use of l-carnitine as stabilizing agent of proteins Abandoned AU2001223953A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2000/000520 WO2002048190A1 (en) 2000-12-15 2000-12-15 Use of l-carnitine as stabilizing agent of proteins

Publications (1)

Publication Number Publication Date
AU2001223953A1 true AU2001223953A1 (en) 2002-06-24

Family

ID=11133601

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001223953A Abandoned AU2001223953A1 (en) 2000-12-15 2000-12-15 Use of l-carnitine as stabilizing agent of proteins

Country Status (15)

Country Link
US (1) US7833977B2 (en)
EP (1) EP1341813B1 (en)
AT (1) ATE339445T1 (en)
AU (1) AU2001223953A1 (en)
CA (1) CA2434911C (en)
CY (1) CY1106235T1 (en)
DE (1) DE60030787T2 (en)
DK (1) DK1341813T3 (en)
ES (1) ES2272351T3 (en)
HU (1) HU230002B1 (en)
MX (1) MXPA03006266A (en)
PL (1) PL199984B1 (en)
PT (1) PT1341813E (en)
SK (1) SK287787B6 (en)
WO (1) WO2002048190A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261242B2 (en) 2000-05-03 2006-12-14 Expressive Constructs, Inc. A method for improving recombinant protein stability and solubility
WO2002048190A1 (en) 2000-12-15 2002-06-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine as stabilizing agent of proteins
WO2005004894A2 (en) * 2003-05-12 2005-01-20 Expressive Constructs, Inc. Methods for increasing cell and tissue viability
WO2011075430A1 (en) * 2009-12-14 2011-06-23 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
US20200140500A1 (en) * 2012-07-17 2020-05-07 The Regents Of The University Of Michigan High throughput methods, protein inhibitors, and uses thereof
WO2014152818A1 (en) 2013-03-14 2014-09-25 The University Of Massachusetts Methods of inhibiting cataracts and presbyopia
AU2016354479B2 (en) 2015-11-13 2021-10-07 The University Of Massachusetts Bifunctional molecules containing PEG for use in inhibiting cataracts and presbyopia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1235153B (en) * 1988-11-15 1992-06-22 Sigma Tau Ind Farmaceuti USE OF ACETYL L-CARNITINE IN THE THERAPEUTIC TREATMENT OF CATARACT AND PHARMACEUTICAL COMPOSITIONS USEFUL IN SUCH TREATMENT
US20040058015A1 (en) * 2000-06-01 2004-03-25 Yuanjin Tao Compositions and methods for treating eye discomfort and eye disease
WO2002048190A1 (en) 2000-12-15 2002-06-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine as stabilizing agent of proteins
ITRM20010294A1 (en) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti USE OF ACETYL L-CARNETINE IN ASSOCIATION WITH BIOTIN FOR THE TREATMENT OF PATIENTS WITH DIABETES TYPE II INSULIN RE
US6923960B2 (en) * 2001-10-03 2005-08-02 Vsl Pharmaceuticals Inc. Antioxidant combination composition and use thereof
US20050163873A1 (en) * 2004-01-14 2005-07-28 Robert Ritch Methods and formulations for treating glaucoma
ITRM20040327A1 (en) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti USE OF ACETYL L-CARNITINE FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF NEUROPATHIC PAIN IN DIABETIC PATIENTS.
US8569366B2 (en) * 2005-04-26 2013-10-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes

Also Published As

Publication number Publication date
WO2002048190A1 (en) 2002-06-20
EP1341813A1 (en) 2003-09-10
ES2272351T3 (en) 2007-05-01
HUP0400737A3 (en) 2013-06-28
PT1341813E (en) 2007-01-31
US7833977B2 (en) 2010-11-16
PL199984B1 (en) 2008-11-28
MXPA03006266A (en) 2004-06-25
CY1106235T1 (en) 2011-06-08
EP1341813B1 (en) 2006-09-13
CA2434911C (en) 2009-12-08
SK287787B6 (en) 2011-09-05
HUP0400737A2 (en) 2004-07-28
PL367204A1 (en) 2005-02-21
CA2434911A1 (en) 2002-06-20
HU230002B1 (en) 2015-04-28
ATE339445T1 (en) 2006-10-15
US20040120967A1 (en) 2004-06-24
DK1341813T3 (en) 2007-01-15
DE60030787T2 (en) 2007-09-13
DE60030787D1 (en) 2006-10-26
SK8902003A3 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
ID24901A (en) METHOD OF TREATMENT OF HIGH COAGAGULATION OR DEFICIENCY OF PROTEIN C OBTAINED
AU766216C (en) Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
WO2002087563A3 (en) Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
WO2007025142A3 (en) Gel compositions comprising a combination of an antiseptic and an anesthetic agent for treating surface areas in medical and surgical procedures
AU2002341366A1 (en) Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucuous membranes
NZ506408A (en) Pharmaceutical compositions
CY1106235T1 (en) USE OF L-CARNITINE AS A PROTEIN STABILIZING AGENT
AU2003207417A1 (en) Use of tryptophan rich peptides
WO2002102743A3 (en) DEUTERATED N-SUBSTITUTED AND α-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS
WO2000000214A3 (en) Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
WO2003063780A3 (en) Therapeutic composition for treatment of cancer by arginine depletion
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
ZA991749B (en) Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy.
EP1180017B8 (en) Preparations with povidon iodine for wound treatment
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
ES2182840T3 (en) FACTOR XIII FOR THE TREATMENT OF SKIN WOUNDS.
WO2001028578A3 (en) A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
ATE295159T1 (en) BUPROPION FOR THE TREATMENT OF VIRAL DISEASES
WO2001070951A3 (en) Agent for the diagnosis and therapy of viral diseases
AU2003294834A1 (en) Anthranilic acid amide derivatives and their pharmaceutical use
WO2003097690A3 (en) Pth derivatives resistant to skin proteases
DE60222662D1 (en) USE OF L-AZETYLCARNITINE FOR THE MANUFACTURE OF A MEDICAMENT FOR PREVENTIVE POST-SURGERY PAIN TREATMENT
EP0974360A3 (en) Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
DE60040910D1 (en) INACTIVATED CYTOKINS FOR IMMUNIZATION